News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MannKind Corporation (MNKD) Reports 2013 Second Quarter Financial Results


8/12/2013 6:41:14 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter ended June 30, 2013.

For the second quarter of 2013, total operating expenses were $41.6 million, compared to $44.1 million for the second quarter of 2012, a decrease of $2.5 million. Research and development (R&D) expenses were $27.1 million for the second quarter of 2013 compared to $26.6 million for the same quarter in 2012, an increase of $0.5 million primarily due to an increase in non-cash stock compensation expense partially offset by a decrease in clinical trial related expenses.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES